EPO and anemia: As anemia appears not to be the sole driver of increased EPO levels during HUS and patients with pronounced kidney damage showed the lowest EPO levels, we next wanted to analyze the therapeutic potential of EPO and the non-hematopoietic EPO derivative pHBSP in a murine model of HUS.